Over the weekend, Bristol Myers Squibb & Co (NYSE: BMY) shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback